Asarina Pharma

About Us

Asarina Pharma Asarina Pharma is a Swedish biotech company developing Sepranolone for Allopregnanolone-related stress, compulsion and neurological disorders. Our product pipeline is built on over 40 years of research, and with our new family of GAMSA compounds (GABA-A Modulating Steroid Antagonists) we aim to deliver a new generation of efficacious and safe drugs for still widely untreated neuroendocrinological conditions from Tourette syndrome to OCD..

Pick a time period -

Tags ( Active)

All Regulatory Non-Regulatory

Asarina Pharma AB (publ) Interim Report Q1 2020 released

Tue, May 26, 2020 08:00 CET

Asarina Pharma CEO Peter Nordkild: “In April 2020 we released inconclusive topline results from our phase IIb study in PMDD. Although disappointing, these results do not invalidate our 40 years’ research into allopregnanolone and Sepranolone. Allopregnanolone remains implicated in a wide range of stress- and compulsion-related disorders, from Tourette to menstrual migraine to OCD, PTSD, compulsive gambling, addiction and more. As the endogenous compound that modulates the body’s allopregnanolone levels, our novel treatment Sepranolone remains a driving scientific and commercial force for us.

There are no items matching the current filter

There are no more items matching the current filter

Back to top

Share

About Us

Asarina Pharma AB (publ) Interim Report Q1 2020 released